NO20070153L - Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon - Google Patents

Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Info

Publication number
NO20070153L
NO20070153L NO20070153A NO20070153A NO20070153L NO 20070153 L NO20070153 L NO 20070153L NO 20070153 A NO20070153 A NO 20070153A NO 20070153 A NO20070153 A NO 20070153A NO 20070153 L NO20070153 L NO 20070153L
Authority
NO
Norway
Prior art keywords
zcytorl4
binding partners
soluble
antibodies
methods
Prior art date
Application number
NO20070153A
Other languages
English (en)
Norwegian (no)
Inventor
Scott R Presnell
Steven K Burkhead
Steven D Levin
Rolf E Kuestner
Zeren Gao
Stephen R Jaspers
Janine Billsborough
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20070153L publication Critical patent/NO20070153L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20070153A 2004-06-10 2007-01-09 Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon NO20070153L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57880504P 2004-06-10 2004-06-10
PCT/US2005/020521 WO2005123778A2 (fr) 2004-06-10 2005-06-10 Zcytor14 solubles, anti-zcytor14 et partenaires de liaison et leurs procedes d'utilisation dans l'inflammation

Publications (1)

Publication Number Publication Date
NO20070153L true NO20070153L (no) 2007-03-09

Family

ID=35407029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070153A NO20070153L (no) 2004-06-10 2007-01-09 Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Country Status (11)

Country Link
US (4) US7910540B2 (fr)
EP (1) EP1765865A2 (fr)
JP (1) JP4903703B2 (fr)
CN (1) CN101001871A (fr)
AU (1) AU2005254998B2 (fr)
BR (1) BRPI0511952A (fr)
CA (1) CA2569867A1 (fr)
IL (2) IL179356A (fr)
MX (1) MXPA06014465A (fr)
NO (1) NO20070153L (fr)
WO (1) WO2005123778A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7324615B2 (en) * 2003-12-15 2008-01-29 Microchip Technology Incorporated Time signal receiver and decoder
EP1765865A2 (fr) * 2004-06-10 2007-03-28 ZymoGenetics, Inc. Zcytor14 solubles, anti-zcytor14 et partenaires de liaison et leurs procedes d'utilisation dans l'inflammation
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
WO2006088925A2 (fr) 2005-02-14 2006-08-24 Wyeth Caracterisation d'interactions de il-17f et de il-17r
BRPI0616589A2 (pt) 2005-09-28 2011-06-28 Zymogenetics Inc polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
WO2007117762A1 (fr) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Recepteur soluble tronque de l'il-17ra et procedes d'utilisation contre l'inflammation
WO2008039553A1 (fr) * 2006-02-10 2008-04-03 Zymogenetics, Inc. Il-17rcx4 soluble et procédés d'utilisation dans l'inflammation
JP2009534297A (ja) * 2006-03-10 2009-09-24 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
EP2004231A4 (fr) 2006-04-07 2013-07-10 Nektar Therapeutics Conjugues d'un anticorps anti-tnf-alpha
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
CA2679588A1 (fr) 2007-03-26 2008-10-02 Zymogenetics, Inc. Proteines de fusion solubles il-17ra/rc et procedes afferents
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
US8460647B2 (en) * 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
AU2007352412B2 (en) * 2007-04-27 2013-05-16 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
EP2170958A1 (fr) * 2007-06-13 2010-04-07 Amgen Inc. Complexe récepteur hétéromère de l'il-17
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
EP2182943B1 (fr) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Procédés et compositions pour traiter des troubles associés à une fibrose en utilisant des antagonistes de l'il-17
WO2009026412A1 (fr) * 2007-08-21 2009-02-26 Children's Medical Center Corporation Traitement de l'hyperréactivité des voies aériennes
EP2203476B1 (fr) 2007-09-25 2016-10-26 Genzyme Corporation Compositions et procédés pour inhiber les voies d'interleukines
CA2711696C (fr) 2008-01-09 2021-10-26 Reza Dana Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
US20130011413A1 (en) * 2010-02-03 2013-01-10 The University Of Tokyo Method and Pharmaceutical Composition for Treatment of Intestinal Disease
CN102188707B (zh) * 2011-02-25 2015-08-05 中国医学科学院基础医学研究所 Il-17抑制剂在制备治疗流感的药物中的用途
EP2809660B1 (fr) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Composés macrocycliques pour une modulation d'il-17
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
WO2020219943A1 (fr) * 2019-04-26 2020-10-29 Prolynx Llc Conjugués de cytokine à libération lente

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
ES2229264T5 (es) 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US20030100051A1 (en) 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO1998049307A1 (fr) 1997-05-01 1998-11-05 Zymogenetics, Inc. Recepteurs de mammiferes analogues de la cytokine
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1015488B1 (fr) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US20030040471A1 (en) 1998-04-29 2003-02-27 Watson James D. Compositions isolated from skin cells and methods for their use
EP1078046A4 (fr) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 proteines humaines secretees
US7247442B1 (en) 1998-05-12 2007-07-24 Human Genome Sciences, Inc. Antibodies to HHPEN62 polypeptide
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US20020182673A1 (en) 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030199041A1 (en) 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
DE60034564T2 (de) * 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
ES2333772T3 (es) 1999-12-23 2010-03-01 Genentech, Inc. Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
US20040048249A1 (en) 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
AU2001247306A1 (en) 2000-03-08 2001-09-17 Human Genome Sciences, Inc. Immune system-related polynucleotides, polypeptides, and antibodies
US20040197306A1 (en) 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
US20030092881A1 (en) * 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
US20020146763A1 (en) 2000-07-06 2002-10-10 Zeren Gao Murine cytokine receptor
WO2002038764A2 (fr) 2000-11-10 2002-05-16 The Regents Of The University Of California Proteine de type recepteur il-17, utilisation de celle-ci et modulation de l'activite catabolique des cytokines il-17 sur l'os et le cartilage
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US6681210B2 (en) 2001-09-04 2004-01-20 Andrew Jeffrey Kelly Modular service payroll system
US20040097447A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
EP1765865A2 (fr) 2004-06-10 2007-03-28 ZymoGenetics, Inc. Zcytor14 solubles, anti-zcytor14 et partenaires de liaison et leurs procedes d'utilisation dans l'inflammation
CN101218254A (zh) 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
BRPI0616589A2 (pt) 2005-09-28 2011-06-28 Zymogenetics Inc polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
WO2008039553A1 (fr) 2006-02-10 2008-04-03 Zymogenetics, Inc. Il-17rcx4 soluble et procédés d'utilisation dans l'inflammation
CA2679588A1 (fr) 2007-03-26 2008-10-02 Zymogenetics, Inc. Proteines de fusion solubles il-17ra/rc et procedes afferents

Also Published As

Publication number Publication date
BRPI0511952A (pt) 2008-01-29
EP1765865A2 (fr) 2007-03-28
JP4903703B2 (ja) 2012-03-28
IL208859A0 (en) 2011-01-31
JP2008509227A (ja) 2008-03-27
MXPA06014465A (es) 2007-05-16
IL179356A0 (en) 2007-03-08
US20070048826A1 (en) 2007-03-01
WO2005123778A3 (fr) 2006-02-09
US20110177083A1 (en) 2011-07-21
US7910540B2 (en) 2011-03-22
WO2005123778A2 (fr) 2005-12-29
AU2005254998B2 (en) 2011-10-27
IL179356A (en) 2011-07-31
CN101001871A (zh) 2007-07-18
IL208859A (en) 2013-01-31
US8268773B2 (en) 2012-09-18
US20070048257A1 (en) 2007-03-01
AU2005254998A1 (en) 2005-12-29
CA2569867A1 (fr) 2005-12-29
US20060002925A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
NO20072602L (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NO20054892D0 (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
WO2005052000A3 (fr) Anticorps et partenaires de liaison anti-il 20 et procedes d'utilisation dans l'inflammation
EA200800956A1 (ru) Антагонисты il-17a и il-17f и способы их использования
NO20085309L (no) High affinity antibodies to human IL-6 receptor
WO2008039553A8 (fr) Il-17rcx4 soluble et procédés d'utilisation dans l'inflammation
WO2007106769A3 (fr) Anticorps se liant à la fois avec il-17a et il-17f et procédés d'utilisation
NO20090224L (no) Anti-IL-6 monoklonale antistoffer og anvendelser derav
WO2004045525A3 (fr) Anticorps anti-chimiokines et anticorps anti-recepteurs associes et utilisations de ces anticorps pour inhiber des inflammations
WO2008134659A8 (fr) Antagonistes à il-17a, il-17f et il-23p19, et procédés d'utilisation de ceux-ci
WO2008133684A8 (fr) Anticorps qui se lient à la fois à il-17a et il-17f et leurs procédés d'utilisation
WO2008049070A3 (fr) Antagonistes de l'il-17c et leurs procédés d'utilisation
NO20045043L (no) Pyrimidinonforbindelser, sammensetninger og fremgangsmater
WO2006086396A3 (fr) Anticorps et partenaires de liaison anti-il-20, anti-il-22 et anti-il-22ra, et methodes d'utilisation de ces anticorps et partenaires de liaison dans des processus inflammatoires
WO2006044840A3 (fr) Zcytor21, anticorps anti-zcytor21 et partenaires de liaison solubles ainsi que procedes de leur utilisation lors d'une inflammation
TW202620051A (zh) 介白素-4受體α抗體的使用方法

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application